Skip to main content
Erschienen in: Supportive Care in Cancer 4/2009

01.04.2009 | Original Article

A patient-reported outcome instrument to assess the impact of oropharyngeal mucositis on health-related quality of life: a longitudinal psychometric evaluation

verfasst von: Karis K. F. Cheng, S. F. Leung, Raymond H. S. Liang, Josepha W. M. Tai, Rebecca M. W. Yeung, David R. Thompson

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

An oropharyngeal mucositis (OM)-specific health-related quality of life measure (OMQoL) has been developed to assess the impact of OM from the perspective of patients. The current paper describes the convergent, concurrent, and known-group validities and responsiveness in relation to clinical and health outcomes.

Materials and methods

A multicenter approach was used, and 137 patients treated with different cancer therapies completed the OMQoL and the European Organization for Research and Treatment of Cancer Quality of Life questionnaire [EORTC QLQ-C30 (Ch)] twice over a 4-week period or weekly over a 7-week period, along with concurrent measures of OM and its related symptoms.

Main results

The OM-related symptom scores correlated highly with the OMQoL, confirming its convergent validity (r = −0.724–−0.971, p < 0.01). Moderate correlations between the subscales of the OMQoL and EORTC QLQ-C30 (Ch) were indicative of good concurrent validity (r = 0.450–0.724, p < 0.01). The OMQoL was able to distinguish between patients with different severities of OM (p < 0.01) and types of cancer therapy (p < 0.01), providing evidence of good known-group validity. The changes in effects sizes corresponding to changes in OM curves indicate that the OMQoL is responsive to changes in OM status.

Conclusions

These findings suggest that the OMQoL has very good psychometric properties and can be used as a health-related quality of life assessment for cancer patients with OM. Much work is still needed in strengthening the psychometric qualities and interpretability of the OMQoL by demonstrating its ability to detect outcome changes over time.
Literatur
1.
Zurück zum Zitat Blijlevens NM, Donnelly JP, De Pauw (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25:1269–1278 doi:10.1038/sj.bmt.1702447 PubMedCrossRef Blijlevens NM, Donnelly JP, De Pauw (2000) Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25:1269–1278 doi:10.​1038/​sj.​bmt.​1702447 PubMedCrossRef
3.
Zurück zum Zitat Cheng KKF, Leung SF, Thompson DR et al (2007) A new measure of health-related quality of life for patients with oropharyngeal mucositis (OMQoL): development and preliminary psychometric evaluation. Cancer 109:2590–2599 doi:10.1002/cncr.22730 PubMedCrossRef Cheng KKF, Leung SF, Thompson DR et al (2007) A new measure of health-related quality of life for patients with oropharyngeal mucositis (OMQoL): development and preliminary psychometric evaluation. Cancer 109:2590–2599 doi:10.​1002/​cncr.​22730 PubMedCrossRef
4.
Zurück zum Zitat Chie WC, Hong RL, Lai CC et al (2003) Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Qual Life Res 12:93–98 doi:10.1023/A:1022070220328 PubMedCrossRef Chie WC, Hong RL, Lai CC et al (2003) Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Qual Life Res 12:93–98 doi:10.​1023/​A:​1022070220328 PubMedCrossRef
6.
Zurück zum Zitat Dodd MJ, Dibble S, Miaskowski C et al (2001) A comparison of the affective state and quality of life of chemotherapy patients who do not and do not develop chemotherapy-induced oral mucositis. J Pain Symptom Manage 21:498–505 doi:10.1016/S0885-3924(01)00277-9 PubMedCrossRef Dodd MJ, Dibble S, Miaskowski C et al (2001) A comparison of the affective state and quality of life of chemotherapy patients who do not and do not develop chemotherapy-induced oral mucositis. J Pain Symptom Manage 21:498–505 doi:10.​1016/​S0885-3924(01)00277-9 PubMedCrossRef
7.
Zurück zum Zitat Duncan GG, Epstein JB, Dongsheng T et al (2005) Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 27(5):421–428 doi:10.1002/hed.20162 PubMedCrossRef Duncan GG, Epstein JB, Dongsheng T et al (2005) Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 27(5):421–428 doi:10.​1002/​hed.​20162 PubMedCrossRef
10.
Zurück zum Zitat EORTC (2001) EORTC QLQ-C30 scoring manual. Brussels EORTC (2001) EORTC QLQ-C30 scoring manual. Brussels
11.
Zurück zum Zitat Epstein JB, Beaumont JL, Gwede CK et al (2007) Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 109:1914–1922 doi:10.1002/cncr.22620 PubMedCrossRef Epstein JB, Beaumont JL, Gwede CK et al (2007) Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 109:1914–1922 doi:10.​1002/​cncr.​22620 PubMedCrossRef
12.
Zurück zum Zitat Fayers PM, Machin D (2000) Quality of life: assessment, analysis and interpretation. Wiley, Chichester Fayers PM, Machin D (2000) Quality of life: assessment, analysis and interpretation. Wiley, Chichester
13.
Zurück zum Zitat Fletcher A, Gore S, Jones D et al (1992) Quality of life measures in health care II: design, analysis, and interpretation. BMJ 305:1145–1148PubMed Fletcher A, Gore S, Jones D et al (1992) Quality of life measures in health care II: design, analysis, and interpretation. BMJ 305:1145–1148PubMed
15.
Zurück zum Zitat Lipscomb J, Gotay CC, Snyder CF (2007) Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA Cancer J Clin 57:278–300PubMedCrossRef Lipscomb J, Gotay CC, Snyder CF (2007) Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA Cancer J Clin 57:278–300PubMedCrossRef
16.
Zurück zum Zitat Matthews JNS, Altman DG, Campbell MJ et al (1990) Analysis of serial measurements in medical research. BMJ 300:230–235PubMed Matthews JNS, Altman DG, Campbell MJ et al (1990) Analysis of serial measurements in medical research. BMJ 300:230–235PubMed
18.
Zurück zum Zitat Nunnally JC, Bernstein IH (1994) Psychometric theory (3rd edn). McGraw-Hill, New York Nunnally JC, Bernstein IH (1994) Psychometric theory (3rd edn). McGraw-Hill, New York
19.
Zurück zum Zitat Osoba D, Zee B, Pater D et al (1994) Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353–364 doi:10.1007/BF00451727 PubMedCrossRef Osoba D, Zee B, Pater D et al (1994) Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353–364 doi:10.​1007/​BF00451727 PubMedCrossRef
20.
Zurück zum Zitat Ramirez-Amador V, Esquivel-Pedraza L, Moha A et al (1996) Chemotherapy-associated oral mucosal lesions in patients with leukemia or lymphoma. Eur J Cancer Oral Oncol 32:322–337CrossRef Ramirez-Amador V, Esquivel-Pedraza L, Moha A et al (1996) Chemotherapy-associated oral mucosal lesions in patients with leukemia or lymphoma. Eur J Cancer Oral Oncol 32:322–337CrossRef
21.
22.
25.
Zurück zum Zitat Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed
27.
28.
Zurück zum Zitat Stiff PJ, Erder H, Bensinger WI et al (2006) Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 37:393–401 doi:10.1038/sj.bmt.1705250 PubMedCrossRef Stiff PJ, Erder H, Bensinger WI et al (2006) Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 37:393–401 doi:10.​1038/​sj.​bmt.​1705250 PubMedCrossRef
29.
Zurück zum Zitat Streiner DL, Norman GR (2003) Health measurement scales: a practical guide to their development and use (3rd edn). Oxford University Press, Oxford Streiner DL, Norman GR (2003) Health measurement scales: a practical guide to their development and use (3rd edn). Oxford University Press, Oxford
30.
31.
Zurück zum Zitat Trotte A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262 doi:10.1016/S0167-8140(02)00404-8 CrossRef Trotte A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262 doi:10.​1016/​S0167-8140(02)00404-8 CrossRef
32.
Zurück zum Zitat World Health Organization (1979) Handbook for reporting results of cancer treatment. Offset Publication, Geneva World Health Organization (1979) Handbook for reporting results of cancer treatment. Offset Publication, Geneva
Metadaten
Titel
A patient-reported outcome instrument to assess the impact of oropharyngeal mucositis on health-related quality of life: a longitudinal psychometric evaluation
verfasst von
Karis K. F. Cheng
S. F. Leung
Raymond H. S. Liang
Josepha W. M. Tai
Rebecca M. W. Yeung
David R. Thompson
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0485-2

Weitere Artikel der Ausgabe 4/2009

Supportive Care in Cancer 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.